All European Medicines Agency articles
-
NewsAcoziborole Winthrop receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
The European Medicines Agency has granted a positive opinion to Acoziborole Winthrop (acoziborole) as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults as well as in adolescents 12 years and older weighing at least 40 kilograms.
-
NewsEMA gives positive opinion to first oral treatment of acute form of sleeping sickness
The EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).
-
NewsUK lagging on availability of treatment for rare diseases, industry group warns
A group of companies developing innovative new medicines for rare diseases is calling for the UK to lead greater collaboration between stakeholders, and uptake of best practice to improve access to new treatments for patients.
-
NewsStudy of simple acoziborole regime raises hope for elimination of sleeping sickness in Africa
The Drugs for Neglected Diseases initiative (DNDi) and Sanofi have announced treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness.